Six-Month Response to Delamanid Treatment in MDR TB Patients

被引：29

作者：

Hewison, Cathy ^{[1
]}

Ferlazzo, Gabriella ^{[2
]}

Avaliani, Zaza ^{[3
]}

Hayrapetyan, Armen ^{[4
]}

Jonckheere, Sylvie ^{[5
]}

Khaidarkhanova, Zarema ^{[6
]}

Mohr, Erika ^{[2
]}

Sinha, Animesh ^{[7
]}

Skrahina, Alena ^{[8
]}

Vambe, Debrah ^{[9
]}

Vasilyeva, Irina ^{[10
]}

Lachenal, Nathalie ^{[11
]}

Varaine, Francis ^{[1
]}

机构：

[1] Med Sans Frontieres, Paris, France

[2] Med Sans Frontieres, Cape Town, South Africa

[3] Natl Ctr TB & Lung Dis, Tbilisi, Georgia

[4] Minist Hlth, Natl TB Control Ctr, Yerevan, Armenia

[5] Med Sans Frontieres, Johannesburg, South Africa

[6] Republican TB Dispensary, Grozny, Chechnya, Russia

[7] Med Sans Frontieres, Minsk, BELARUS

[8] Republican Res & Pract Ctr Pulmonol & TB, Minsk, BELARUS

[9] Swaziland Natl TB Control Program, Mbabane, Swaziland

[10] IM Sechenov First MSMU, Res Inst Phthisiopulmonol, Moscow, Russia

[11] Med Sans Frontieres, Geneva, Switzerland

来源：

EMERGING INFECTIOUS DISEASES | 2017年 / 23卷 / 10期

关键词：

D O I：

10.3201/eid2310.170468

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability and treatment response at 6 months.

引用

页码：1746 / 1748

页数：3

共 50 条

[1] Six-Month Treatment Patterns and Outcomes for Patients with Fibromyalgia.
Robinson, Rebecca
Kroenke, Kurt
Williams, David A.
Chen, Yi
Wohlreich, Madelaine M.
McCarberg, Bill
Mease, Philip J.
ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S744 - S744
[2] Six-month outcomes for patients who switched to olanzapine treatment
Noordsy, DL
O'Keefe, C
Mueser, KT
Xie, HY
PSYCHIATRIC SERVICES, 2001, 52 (04) : 501 - 507
[3] Effects of six-month fish oil treatment in hemodialysis patients
Kadar, Andras
Karpati, Istvan
Kusicza, Eszter
Katko, Monika
Matyus, Janos
Ujhelyi, Laszlo
Trinn, Csilla
Balla, Jozsef
Varga, Zsuzsa
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 332 - 332
[4] Trajectory analysis of treatment response during a six-month study of nightly eszopiclone in patients with chronic insomnia
Buysse, DJ
Amato, DA
Wilson, P
Wessel, T
SLEEP, 2004, 27 : 262 - 263
[5] Early treatment response of ocrelizumab in persons with multiple sclerosis: six-month results
Ozakbas, S.
Ozcelik, S.
Kaya, E.
Ozdogar, A. T.
Sagici, O.
Baba, C.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 278 - 278
[6] Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea
Mok, Jeongha
Kang, Hyungseok
Hwang, Soo Hee
Park, Jin Su
Kang, Bohyoung
Lee, Taehoon
Koh, Won-Jung
Yim, Jae-Joon
Jeon, Doosoo
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (02) : 503 - 508
[7] Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)
Field, Stephen K.
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2013, 5 : 137 - 149
[8] Assessment of different cognitive domains in dementia patients after six-month treatment
Bragin, V
Dzhafarova, N
Bragin, I
Perelmuter, O
NEUROBIOLOGY OF AGING, 2002, 23 (01) : S260 - S260
[9] Six-month effective treatment of corneal graft rejection
Meng, Tuo
Zheng, Jinhua
Chen, Min
Zhao, Yang
Sudarjat, Hadi
Alex, M. R. Aji
Kulkarni, Vineet
Oh, Yumin
Xia, Shiyu
Ding, Zheng
Han, Hyounkoo
Anders, Nicole
Rudek, Michelle A.
Chow, Woon
Stark, Walter
Ensign, Laura M.
Hanes, Justin
Xu, Qingguo
SCIENCE ADVANCES, 2023, 9 (12)
[10] Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
Hafkin, Jeffrey
Hittel, Norbert
Martin, Alexandra
Gupta, Rajesh
EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (01)

← 1 2 3 4 5 →